LATEST PSYCHEDELICS STOCKS NEWS

Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

TORONTO, Nov. 24, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it will submit the Type C meeting request package to the U.S. Food &a... Read More...

Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

TORONTO, Nov. 22, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has responded that a ... Read More...

Field Trip Health & Wellness Ltd. Strengthens Leadership Team With Two Executive Appointments, Schedules Fiscal Second Quarter 2023 Conference Call

Appoints Stacey Hoisak as Senior Vice President, General Counsel, and Dr. Monique Moller as Vice President, Integrative HealthSchedules Fiscal Second Quarter 2023 Conference Call for Tuesday, November 29, 2022, at 8:30 AM ET TORONTO, Nov. 22, 2022 -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or “Field Trip”), a glo... Read More...

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022

VANCOUVER, BC, Nov. 22, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will participate in a Water Tower Research Fireside Chat on Thursday, Dece... Read More...

Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement

DENVER, Nov. 21, 2022 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in con... Read More...

Pure Extracts Receives Approval from Manitoba Liquor & Lotteries to list Pure Pulls Vapes and Pure Chews Edibles

VANCOUVER, British Columbia, Nov. 16, 2022 -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and functional mushrooms, is pleased to announce that its wholly-owned subsidiary, Pure Extracts Manufacturing Corp., has rece... Read More...

Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022

TORONTO, November 15, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, today announced that the Company presented a poster highlighting preclinical data for its deuterated psilocybin analog, CYB003 at Neuroscience 20... Read More...

Mydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022

DENVER, Nov. 14, 2022 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported company highlights and financial results for the nine months ended September 30, 2022. Company Highlights In 2022, Mydecin... Read More...

Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation

ENGLEWOOD CLIFFS, NJ, Nov. 11, 2022 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced initial dosing in its IND-enabling study of SP-26, its novel time-released, topical formulation of ketamine. The ob... Read More...

Miami on November 3-5, 2022

 VANCOUVER, BC, Oct. 31, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in Wonderland: Miami hosted by Microdose to be held at the Mana Wynwood Convention Cent... Read More...

Delic Labs President and CSO Dr. Markus Roggen to Discuss the Importance of R&D for Business Growth at MJBizCon

Dr. Markus Roggen, President and Chief Science Officer for Delic Labs, will participate in a panel discussion about building scientific trust and using research and development to differentiate a brand and maximize revenuesVANCOUVER, BC, Oct. 27, 2022 - Delic Holdings Corp ("Delic") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new m... Read More...

COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022

COMPASS PathwaysLONDON, Oct. 26, 2022 -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2022, and provide an update on recent business developments on 3 Nov... Read More...

Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study

ENGLEWOOD CLIFFS, NJ, Oct. 20, 2022 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer's disease (AD), as... Read More...

Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics

ENGLEWOOD CLIFFS, NJ, Oct. 18, 2022 -- Silo Pharma, Inc. (NASDAQ: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced it has entered into an agreement with Columbia University pursuant to which Silo has been granted an extension for i... Read More...

Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

TORONTO, Oct. 14, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has finalized an amended protocol to the U.S. Food & Drug Admi... Read More...

Lobe Sciences Announces the Completion of cGMP Production of Clinical Supplies For Upcoming Clinical Trials

Appointment of Philip J. Young, CEO, as Board ChairmanVancouver, British Columbia--(Newsfile Corp. - October 13, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that it... Read More...

Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia

Studies of SP-26, the company’s proprietary, time-released ketamine show positive results in reducing neuropathic nerve pain  ENGLEWOOD CLIFFS, NJ, Oct. 10, 2022 --  Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, toda... Read More...

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, October 13, 2022

VANCOUVER, BC, Oct. 7, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will participate in a Water Tower Research Fireside Chat on Thur... Read More...

Lobe Sciences Announces the Appointment of Baxter F. Phillips III to Its Board of Directors

Vancouver, British Columbia--(Newsfile Corp. - October 5, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that Baxter F. Phillips III has been appointed to the Board of... Read More...

Pure Extracts Receives Purchase Order for a New Listing of Cured Resin Vape Carts from the Ontario Cannabis Store

VANCOUVER, British Columbia, Oct. 05, 2022 -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and functional mushrooms, is pleased to announce that its wholly-owned subsidiary, Pure Extracts Manufacturing Corp., has rece... Read More...

Field Trip Health & Wellness to Participate in the Cantor Fitzgerald Symposium on Mental Health Clinics on October 11th

TORONTO, Oct. 04, 2022 -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or “Field Trip”), a global leader in psychedelic therapies, today announced it will participate in a virtual fireside chat at Cantor Fitzgerald’s “Symposium on Mental Health Clinics,” taking place on Tuesday, October 11, 2022. Mujeeb Jafferi, Presi... Read More...

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology

Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine ENGLEWOOD CLIFFS, NJ, Oct. 03, 2022 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it is working ... Read More...

Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option

ENGLEWOOD CLIFFS, NJ, Sept. 30, 2022 -- Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced the closing of its underwritten public offering of 1,150,000 shares of its common stock, which included the full exercise of the un... Read More...

Numinus to Participate in the Cantor Neurology & Psychiatry Conference on October 6-7, 2022

VANCOUVER, BC, Sept. 29, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) ( OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the Cantor Neurology & Psychiatry Conference to be held at The Ritz-Carlton in ... Read More...

Ketamine Wellness Centers (KWC) Expands Insurance Coverage with Medicare for Ketamine Therapy Patients

KWC will serve more patients than any other ketamine therapy provider with addition of Medicare, cements status as nation's largest ketamine clinic network in the U.S.  Medicare coverage will be available for patients in eight cities with more to come GILBERT, Ariz., Sept. 29, 2022 - Ketamine Wellness Centers (KWC), the largest ketamine t... Read More...

PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022

Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion products, ketamine microneedle patch and ketamine wearable pump device for mental health, neurological, and pain disorders Seeking FDA approval for the Company’s ketamine injection and infusion products ... Read More...

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada

Optimi Health Corp.Optimi aiming to become the first vertically integrated psychedelics firm to formulate and trial MDMA for healthy subjectsVANCOUVER, British Columbia, Sept. 22, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce and... Read More...

Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

TORONTO, Sept. 19, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is delighted to announce that it has received approval for its Phase IIa clinical trial from the Medicines and Healthcare pr... Read More...

Numinus Now Offers Ketamine-Assisted Therapy in Toronto

Treatment will be offered at the Neurology Centre of Toronto in Forest Hill VANCOUVER, BC, Sept. 19, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) ( OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that its Toronto clinic, the Neurol... Read More...

Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program

TORONTO, Sept. 16, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s Phase I/II clinical study of oral psiloc... Read More...